Antibodies, Bispecific – Page 3

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

9 months ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development

Johnson & Johnson Highlights Promising Combination of TALVEY and TECVAYLI for Relapsed or Refractory Multiple Myeloma

9 months ago talkbio0Tagged Antibodies, Bispecific, Combined, EMD, Extramedullary Disease in Plasma Cell Myeloma, Frequency of Responses, Refractory Plasma Cell Myeloma, Relapsing course, Response process, Talquetamab, TALVEY, Teclistamab, TECVAYLI

TALVEY (talquetamab), TECVAYLI (teclistamab), Relapsed or Refractory Multiple Myeloma (RRMM), Bispecific Antibody Combination, Extramedullary Disease (EMD), High Response Rates, Durable Responses

Summit’s Ivonescimab Shows Promising Results Over Keytruda in NSCLC, But Global Validation Needed

10 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma

NSCLC, Ivonescimab, Keytruda, Bispecific Antibody, Lung Cancer Treatment

Zanidatamab Demonstrates Promising 30-Month Survival Rate in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

10 months ago talkbio0Tagged Antibodies, Bispecific, HER2-positive, Malignant neoplasm of stomach, Metastatic gastroesophageal adenocarcinoma, Neoplasms, Survival Rate, Zanidatamab

Zanidatamab, HER2-positive, metastatic gastroesophageal adenocarcinoma, bispecific antibody, survival rate, gastric cancer, oncology.

Innovent Biologics Reports Promising Results in Early-Stage Study of Bispecific Antibody IBI363 in Lung Cancer Patients

10 months ago talkbio0Tagged Antibodies, Bispecific, Biological Factors, Early-Stage Study, IBI363, Innovent, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, PD-1/IL-2, α-bias

Innovent Biologics, IBI363, Bispecific Antibody, Lung Cancer, Early-Stage Study, PD-1/IL-2 α-bias, Non-Small Cell Lung Cancer (NSCLC)

Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody

11 months ago talkbio0Tagged Antibodies, Bispecific, Autoimmune Diseases, Capital Management, Forbion, Funding, Navigator Medicines, Rheumatoid Arthritis, Series

Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion

Regeneron Secures EU Approval for Lymphoma Treatment Ordspono Following FDA Rejection

11 months ago talkbio0Tagged Antibodies, Bispecific, Approved, EU, Lymphoma, Odronextamab, Ordspono, Regeneron, Rejection (Psychology), United States Food and Drug Administration

Regeneron, EU approval, lymphoma, bispecific antibody, odronextamab, Ordspono, FDA rejection

FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues

11 months ago talkbio0Tagged Antibodies, Bispecific, Cancer Therapeutic Procedure, Linvoseltamab, Multiple Myeloma, Regeneron, Rejection (Psychology), United States Food and Drug Administration

Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment

Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events

11 months ago talkbio0Tagged Adverse event, amgen, Antibodies, Bispecific, CAR-T, Carvykti, China, Curon Biopharmaceutical, Evaluation procedure, File (record), Legend Biotech, Merck, United States Food and Drug Administration

Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti

Merck Acquires Clinical-Stage CD3xCD19 Bispecific Antibody for $700M

11 months ago talkbio0Tagged Antibodies, Bispecific, CD3xCD19, clinical-stage, Curon Biopharmaceutical, Merck, pharmaceutical acquisition

Merck, CD3xCD19 bispecific antibody, Curon Biopharmaceutical, clinical-stage, pharmaceutical acquisition